구조모아 (StructureMoa)항암 chemical structure spider web
방문Shenzhen BinDeBio Ltd.
CAR-T cell immunotherapy(Shenzhen BinDeBio Ltd.)은 GD2 표적 세포·유전자 치료로, Hepatocellular Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: CAR-T cell functionality required genetic ablation of STING in CAR-T cells and was dependent on cancer cell-intrinsic STING signaling on STING-agonistic treatment. Phase 1 안전성·PK 탐색 단계입니다. 선택한 코호트에서 보고된 효능: ORR 80.3% (ClinicalTrials.gov NCT03483103). 차별점: novel mechanism by which MT nanoparticles enhance the proliferation, and thus the cytotoxicity of PDGFRβ CAR-T cells by.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
GD2
Hepatocellular Carcinoma
Active
2026-09-02
Data Confidence · Medium
Development Signal · Watch
CAR-T cell function for additive therapy against liver fibrosis
lentiviral Tet-On system, we engineered organoids to express essential cytokines RSPO1 and
humanized mouse model
novel mechanism by which MT nanoparticles enhance the proliferation, and thus the cytotoxicity of PDGFRβ CAR-T cells by
CAR-T cell functionality required genetic ablation of STING in CAR-T cells and was dependent on cancer cell-intrinsic STING signaling on STING-agonistic treatment
cytokine release syndrome (CRS), and progression-free survival (PFS) were evaluated
payload may vary depending on tumor type, target antigen expression level, and microenvironmental context, making systematic ex
biomarker that may help individualized risk stratification and inform treatment optimization in CAR-T therapy
resistance to dominant suppressive pathways such as TGF-β and adenosine signalling, improved trafficking and tissue penetration
구조화 데이터
xenograft and syngeneic mouse
mouse
PD
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Shenzhen BinDeBio Ltd.
CAR-T cell immunotherapy(Shenzhen BinDeBio Ltd.)은 GD2 표적 세포·유전자 치료로, Hepatocellular Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: CAR-T cell functionality required genetic ablation of STING in CAR-T cells and was dependent on cancer cell-intrinsic STING signaling on STING-agonistic treatment. Phase 1 안전성·PK 탐색 단계입니다. 선택한 코호트에서 보고된 효능: ORR 80.3% (ClinicalTrials.gov NCT03483103). 차별점: novel mechanism by which MT nanoparticles enhance the proliferation, and thus the cytotoxicity of PDGFRβ CAR-T cells by.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
GD2
Hepatocellular Carcinoma
Active
2026-09-02
Data Confidence · Medium
Development Signal · Watch
CAR-T cell function for additive therapy against liver fibrosis
lentiviral Tet-On system, we engineered organoids to express essential cytokines RSPO1 and
humanized mouse model
novel mechanism by which MT nanoparticles enhance the proliferation, and thus the cytotoxicity of PDGFRβ CAR-T cells by
CAR-T cell functionality required genetic ablation of STING in CAR-T cells and was dependent on cancer cell-intrinsic STING signaling on STING-agonistic treatment
cytokine release syndrome (CRS), and progression-free survival (PFS) were evaluated
payload may vary depending on tumor type, target antigen expression level, and microenvironmental context, making systematic ex
biomarker that may help individualized risk stratification and inform treatment optimization in CAR-T therapy
resistance to dominant suppressive pathways such as TGF-β and adenosine signalling, improved trafficking and tissue penetration
구조화 데이터
xenograft and syngeneic mouse
mouse
PD
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.